

## 2019 Novel Coronavirus (2019-nCoV) Outbreak: CRS Experts

**Sarah A. Lister** Specialist in Public Health and Epidemiology

Updated February 4, 2020

**Congressional Research Service** 

7-.... www.crs.gov R46209 n December 31, 2019, the World Health Organization (WHO) was informed of a cluster of pneumonia cases in Wuhan, China. Illnesses have since been linked to a new strain of coronavirus, designated 2019 Novel Coronavirus, or 2019-nCoV.<sup>1</sup> As of February 4, 2020, WHO reports that more than 20,000 people have been infected, and more than 420 have died. Most cases and deaths have been in China. The disease has spread to several other countries, including the United States. As the scope of the epidemic widened in China, the U.S. Centers for Disease Control and Prevention (CDC) stated on January 30, 2020, that its "assessment remains that the immediate risk to the American public is low."<sup>2</sup> The situation is rapidly changing, however, and both WHO and CDC post frequent updates.<sup>3</sup> For more information about the U.S. response to this new threat, see CRS Insight IN11212, *Another Coronavirus Emerges: U.S. Domestic Response to 2019-nCoV*, and CRS In Focus IF11421, *Novel Coronavirus (2019-nCoV): Developments in China and International Response*.

The following table lists names and contact information for CRS experts on policy concerns involving the outbreak of 2019 Novel Coronavirus (2019-nCoV). Policy areas identified include

- public health, virology, and epidemiology;
- international response activities; domestic response activities; and
- legal issues.

Legislative Issues	Name/Title	Phone	Email	
Public health, virology, epidemiology				
	<b>Sarah A. Lister</b> Specialist in Public Health and Epidemiology	7	/redacted/@crs.loc.gov	
	<b>Kavya Sekar</b> Analyst in Health Policy	7	/redacted/@crs.loc.gov	
International response activities				
General, outbreak response	<b>Sara M. Tharakan</b> Analyst in Global Health and International Development	7	/redacted/@crs.loc.gov	
General, World Health Organization (WHO), international authorities	<b>Tiaji Salaam-Blyther</b> Specialist in Global Health	7	/redacted/@crs.loc.gov	
State Department	<b>Cory R. Gill</b> Analyst in Foreign Affairs	7	/redacted/@crs.loc.gov	
China: general	Susan V. Lawrence Specialist in Asian Affairs	7	/redacted/@crs.loc.gov	
China: economics and trade	Karen M. Sutter Specialist in Asian Trade and Finance	7	/redacted/@crs.loc.gov	

<sup>&</sup>lt;sup>1</sup> World Health Organization (WHO), "Novel Coronavirus (2019-nCoV)," https://www.who.int/westernpacific/ emergencies/novel-coronavirus.

<sup>&</sup>lt;sup>2</sup> Centers for Disease Control and Prevention (CDC), telebriefing transcript, January 30, 2020, https://www.cdc.gov/media/releases/2020/t0130-novel-coronavirus-update-telebriefing.html.

<sup>&</sup>lt;sup>3</sup> WHO, "Novel Coronavirus (2019-nCoV) situation reports," https://www.who.int/emergencies/diseases/novelcoronavirus-2019/situation-reports; and CDC, "2019 Novel Coronavirus (2019-nCoV) Situation Summary," https://www.cdc.gov/coronavirus/2019-ncov/summary.html.

Domestic response activities			
Public health, Health and Human Services (HHS), Centers for Disease Control and Prevention (CDC), funding	<b>Sarah A. Lister</b> Specialist in Public Health and Epidemiology	7	/redacted/@crs.loc.gov
	<b>Kavya Sekar</b> Analyst in Health Policy	7	/redacted/@crs.loc.gov
Medical countermeasures (tests, vaccines, treatments)	<b>Agata Dabrowska</b> Analyst in Health Policy	7	/redacted/@crs.loc.gov
	Frank Gottron Specialist in Science and Technology Policy	7	/redacted/@crs.loc.gov
	<b>Kavya Sekar</b> Analyst in Health Policy	7	/redacted/@crs.loc.gov
	Edward C. Liu Legislative Attorney	7	/redacted/@crs.loc.gov
Biodefense	Frank Gottron Specialist in Science and Technology Policy	7	/redacted/@crs.loc.gov
Border Screening, Customs and Border Protection (CBP)	Audrey Singer Specialist in Immigration Policy	7	/redacted/@crs.loc.gov
Transportation Sector/Aviation	<b>Bart Elias</b> Specialist in Aviation Policy	7	/redacted/@crs.loc.gov
	<b>Rachel Y. Tang</b> Analyst in Transportation and Industry	7	/redacted/@crs.loc.gov
Legal issues			
Isolation and quarantine, medical countermeasures	<b>Edward C. Liu</b> Legislative Attorney	7	/redacted/@crs.loc.gov

## **Author Contact Information**

Sarah A. Lister Specialist in Public Health and Epidemiology /redacted/@crs.loc.gov....

## EveryCRSReport.com

The Congressional Research Service (CRS) is a federal legislative branch agency, housed inside the Library of Congress, charged with providing the United States Congress non-partisan advice on issues that may come before Congress.

EveryCRSReport.com republishes CRS reports that are available to all Congressional staff. The reports are not classified, and Members of Congress routinely make individual reports available to the public.

Prior to our republication, we redacted phone numbers and email addresses of analysts who produced the reports. We also added this page to the report. We have not intentionally made any other changes to any report published on EveryCRSReport.com.

CRS reports, as a work of the United States government, are not subject to copyright protection in the United States. Any CRS report may be reproduced and distributed in its entirety without permission from CRS. However, as a CRS report may include copyrighted images or material from a third party, you may need to obtain permission of the copyright holder if you wish to copy or otherwise use copyrighted material.

Information in a CRS report should not be relied upon for purposes other than public understanding of information that has been provided by CRS to members of Congress in connection with CRS' institutional role.

EveryCRSReport.com is not a government website and is not affiliated with CRS. We do not claim copyright on any CRS report we have republished.